Fluticasone at different doses for chronic asthma in adults and children

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Adams, Nick P ^a   Bestall, Janine C ^b   Jones, Paul ^b   Lasserson, Toby J ^b   Griffiths, Benedict ^c   Cates, Christopher J ^b  

^a UK   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Administration, inhalation; Adult; Androstadienes *administration dosage ; Anti inflammatory agents *administration dosage ; Asthma *drug therapy ; Child; Chronic disease; Humans; Randomized controlled trials as topic

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; PLACEBO; PREDNISOLONE; SALBUTAMOL; STEROID; ACETYLSALICYLIC ACID; BECLOMETASONE; BUDESONIDE; CICLESONIDE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; GOLD SALT; HYDROCORTISONE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; NEDOCROMIL; SALMETEROL; TETRACOSACTIDE; THEOPHYLLINE; TRIAMCINOLONE; ZAFIRLUKAST; ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT;

ASTHMA; CLINICAL TRIAL; DATA EXTRACTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HOARSENESS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; MULTIPLE CYCLE TREATMENT; PHARYNGITIS; PUBLISHING; REVIEW; RISK ASSESSMENT; SORE THROAT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THRUSH; TREATMENT OUTCOME; ADD ON THERAPY; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; HYDROCORTISONE BLOOD LEVEL; INFORMATION PROCESSING; LOW DRUG DOSE; SIDE EFFECT; ADULT; CHILD; CHRONIC DISEASE; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ASTHMA; CHILD; CHRONIC DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 55049138381     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003534.pub3     Document Type: Review

References (132)

1. Agertoft 1997 {published data only} Agertoft L, Pedersen S. Bone, growth and collagen markers in children treated with fluticasone propionate and budesonide.. European Respiratory Journal 1996;9(23 Suppl):295s.
2. * Agertoft L, Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. European Respiratory Journal 1997;10(7):1507-12.
3. FLIS-02. http://ctr.gsk.co.uk 2005.
4. Allen 1998 {published data only} * Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML, Konig P. Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group. Journal of Pediatrics 1998;132(3 Pt 1):472-7.
5. FLD-220. http://ctr.gsk.co.uk 2005.
6. Konig P, Ford L, Galant S, Lawrence M, Lemanske R, Mendelson L, et al.A 1-year comparison of the effects of inhaled fluticasone propionate (FP) and placebo on growth in pre-pubescent children with asthma. European Respiratory Journal 1996;9:S294.
7. Mahajan P, Pearlman D, Okamoto L. The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents. Journal of Allergy & Clinical Immunology 1998;102(1):19-23.
8. Allen 2000 {published data only} Allen T, Wire P, Wolford J, Harding S. Fluticasone propionate (FP) via the diskus device maintained prednisone reduction beyond one year. American Journal of Respiratory and Critical Care Medicine 2000;161(3 Suppl):A185.
9. Ayres 1995 {published data only} Ayres JG, Bateman ED, Lundback B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. European Respiratory Journal 1995;8:579-86.
10. Boner 1999 {published data only} Boner A, de Benedictis F, La Rosa M, Decimo F, Piacentini G, von Berg A, et al.Clincial Trial to compare the efficacy of two doses of fluticasone propionate (FP) 200 mcg/day and 400 mcg/day, administered for 6 weeks to asthmatic children, as assessed by bronchial responsiveness to methacholine. American Journal of Respiratory & Critical Care Medicine 1999;159(3 pt 2):A139.
11. * FLTB3051. Report on a multicentre, randomised, double-blind, parallel-group clinical trial to compare the efficacy and safety of the dry powder formulation of fluticasone propionate (FP) 200μg/day with fluticasone propionate 400μg/day administered for 6 weeks from a multidose powder device (Diskus™) to paediatric patients with chronic asthma. http://ctr.gsk.co.uk 2005.
12. Bukovskis 2002 {unpublished data only} * Bukovskis M, Jurka N, Taivans I. Influence of large and small dose of fluticasone propionate on clinical symptoms of bronchial asthma, lung function, bronchial hyperreactivity and eosinophilia in induced sputum. European Respiratory Journal 2002;20(Suppl 38):P755.
13. Casale 2001 {published data only} Casale TB, Nelson HS, Stricker W, Fourre JA, Newman KB. Dose response of the effect of inhale fluticasone and flunisolide on endogenous cortisol secretion. American Journal of Respiratory and Critical Care Medicine 2000;161(3 Suppl):A776.
14. * Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Annals of Allergy, Asthma and Immunology 2001;87(5):379-85.
15. Chervinsky 1994 {published data only} * Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, Pleskow W. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. Journal of Allergy &Clinical Immunology 1994;94(4):676-83.
16. FLI201. A randomized, double-blind comparative trial of three dosage regimens of inhaled fluticasone propionate versus placebo in adult patients with asthma. http://ctr.gsk.co.uk 2005.
17. Chetta 2003 {published data only} * Chetta A, Zanini A, Foresi A, Del Donno M, Castagnaro A, D'Ippolito R, et al.Vascular component of airway remodelling in asthma is reduced by high dose of fluticasone. American Journal of Respiratory and Critical Care Medicine 2003;167(5):751-7.
18. Foresi A, Pelucchi A, Dorini S, Mastropasqua B, Chetta A, D'Ippolito R, et al.Low-dose (100μg, b.i.d.) inhaled fluticasone propionate (FP) is as affective as high-dose (500μg, b.i.d.) in mild symptomatic asthma. European Respiratory Journal 2001;18(Supp 33):96s.
19. Foresi A, Pelucchi A, Dorini S, Mastropasqua B, Chetta A, Ippolito RD, et al.Effect of low and high dose inhaled fluticasone propionate fp in symptomatic asthma. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23, www.abstracts2view.com 2001.
20. Dahl 1993 {published data only} * Dahl R, Lundback B, Malo JL, Mazza JA, Nieminen MM, Saarelainen P, Barnacle H. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 1993;104:1352-8.
21. FLIT05. www.clinicalstudyresults.org.
22. Derom 1999 {published data only} * Derom E, Van Schoor J, Verhaeghe W, Vincken W, Pauwels R. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. American Journal of Respiratory & Critical Care Medicine 1999;160(1):157- 61.
23. Derom 2005 {published data only} Derom E, Van De Velde V, Marissens S, Engelstatter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients. Pulmonary Pharmacology & Therapeutics 2005;18(5):328-36.
24. * Derom E, Van De Velde V, Marissens S, Vincken W, Pauwels RA. Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients. European Respiratory Journal 2001;18(Suppl 33):147s.
25. 2° for adenosine in asthma patients. American Journal of Respiratory and Critical Care Medicine 2002;165(Suppl 8):A768..
26. Falcoz 2000 {published data only} Falcoz C, Horton J, Mackie A, Harding S, Daley-Yates PT. Pharmacokinetics of fluticasone propionate inhaled via the diskhaler and diskus powder devices in patients with mild-to-moderate asthma. Cinical Pharmacokinetics 2000;39(Suppl 1):31-7.
27. FAP30001 {unpublished data only} FAP30001. A randomized, double-blind, parallel-group trial of inhaled fluticasone propionate/GR106642X 220mcg BID and 440mcg BID in adolescent and adult subjects with asthma. www.clinicalstudyresults.org 2005 [Accessed 14/11/2007].
28. FLIC15 {unpublished data only} FLIC15. www. clinicalstudyresults.org 2005.
29. FLIP01 {published data only} FLIP01. http://ctr.gsk.co. uk 2005.
30. FLIP01a {published data only} FLIP01. http://ctr.gsk.co. uk 2005.
31. FLIP39 {unpublished data only} FLIP39. http://ctr.gsk.co.uk 2005.
32. FLTA3014 {published data only} FLTA3014. www.clinicalstudyresults.org 2005.
33. FLTA3020 {published data only} FLTA3020. http:ctr.gsk.co.uk 2005.
34. FLTA3020a {published data only} FLTA3020. http:ctr.gsk.co.uk 2005.
35. FLTA3022 {unpublished data only} FLTA3022. A Randomized, Double-Blind, Placebo-Controlled Comparative Trial of Fluticasone Propionate 440mcg BID or 880mcg BID versus Placebo Administered via Metered-Dose Inhaler in Propellant 11/12 or GR106642X in Adolescent and Adult Oral Corticosteroid Dependent Asthmatics. http://ctr.gsk.co.uk 2005.
36. FLTA3022a {unpublished data only} FLTA3022. A Randomized, Double-Blind, Placebo-Controlled Comparative Trial of Fluticasone Propionate 440mcg BID or 880mcg BID versus Placebo Administered via Metered-Dose Inhaler in Propellant 11/12 or GR106642X in Adolescent and Adult Oral Corticosteroid Dependent Asthmatics. http://ctr.gsk.co.uk 2005.
37. Galant 1996 {published data only} Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ. Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Annals of Allergy Asthma & Immunology 1996;77(2):112-8.
38. Gershman 2000 {published data only} * Gershman NH, Wong HH, Liu JT, Fahy JV. Low- and high-dose fluticasone propionate in asthma; effects during and after treatment. European Respiratory Journal 2000;15(1):11-8.
39. Giannini 2003 {published data only} Giannini D, Di Franco A, Bacci E, Bartoli ML, Carnevali S, Cianchetti S, et al.Different doses of inhaled fluticasone propionate FP in the management of moderate asthmatic subjects. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23; www.abstracts2view.com 2001.
40. * Giannini D, Di Franco A, Tonelli M, Bartoli ML, Carnevali S, Cianchetti S. Fifty mug b.i.d. of inhaled fluticasone propionate (FP) are effective in stable asthmatics previously treated with a higher dose of FP. Respiratory Medicine 2003;97(5):463-7.
41. Hofstra 2000 {published data only} * Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PG, Kuethe MC, Sterk PJ. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatric Pulmonology 2000;29(6):415-23.
42. Hofstra WB, Sterk PJ, Neijens HJ, Kuethe MC, Mulder PGH, Duiverman EJ. The effect of 24 weeks treatment with 100 mcg or 250 mcg b.d. fluticasone propionate in reducing exercise-induced bronchoconstriction in childhood asthma. American Journal of Respiratory & Critical Care Medicine 1997;155(4 (pt 2)):A267.
43. Ind 2003 {published data only} Ind PW, Dal Negro R, Colman N, Fletcher CP, Browning DC, James MH. Inhaled fluticasone propionate and salmeterol in moderate adult asthma I: lung function and symptoms. American Journal of Respiratory & Critical Care Medicine 1998;157(3):A416.
44. * Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fluticasone propionate treatment in moderate- to-severe asthma. Respiratory Medicine 2003;97(5):555-62.
45. Ind PW, Dal Negro R, Fletcher CP, Browning DC, James MH. Inhaled salmeterol and fluticasone propionate therapy in moderate adult asthma. European Respiratory Journal 1997;10(Suppl 25):1S.
46. SLGQ97. http://ctr.gsk.co.uk 2005.
47. Katz 1998 {published data only} FLIT85. http://ctr.gsk.co.uk 2005.
48. * Katz Y, Lebas FX, Medley HV, Robson R. Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group. Clinical Therapeutics 1998;20(3):424-37.
49. Kemp 2004 {published data only} FLTA3001. http://ctr.gsk.co.uk 2005.
50. * Kemp JP, Osur S, Shrewsbury SB, Herje NE, Duke SP, Harding SM, et al.Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial. Mayo Clinic Proceedings 2004;79(4):458-66.
51. Osur S, Chervinsky P, Herie N, Harding S, Kellerman D. Long term effects of fluticasone propionate (FP) inhalation aerosol in subjects with asthma. American Journal of Respiratory and Critical Care Medicine 1998;157(Suppl 3):A405.
52. Lawrence 1997 {published data only} * Lawrence M, Wolfe J, Webb DR, Chervinsky P, Kellerman D, Schaumberg JP, Shah T. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. American Journal of Respiratory & Critical Care Medicine 1997;156(3 Pt 1):744-51.
53. Nielsen K, Okamoto L, Shah T. Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device. Journal of Asthma 1997;34(3):249-53.
54. Li 1999 {published data only} * Li JTC, Goldstein MF, Gross GN, Noonan MJ, Weisberg S, Edwards L, et al.Effects of fluticasone propionate, triamcinalone acetonide, prednisolone, and placebo on the hypothalamic-pituatary axis. Journal of Allergy and Clinical Immunology 1999;103(4):622-9.
55. Lumry 2006 {published data only} FAP3007. A randomized, double-blind, parallel-group, placebo-controlled 12-week trial of inhaled fluticasone propionate 88mcg BID, 220mcg BID, and 440mcg BID versus placebo in propellant GR106642X in adolescent and adult subjects with asthma who are maintained on inhaled corticosteroid therapy. http://ctr.gsk.co.uk 2005.
56. * Lumry WR, Conway MM, LaForce CF, Pearlman DS, Scott CA, Herje NE, et al.Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids. Annals of allergy, asthma & immunology 2006;96(1):51-9.
57. Nielsen K, Herje N, Wu W. Inhaled fluticasone propionate via metered-dose inhaler with alternate propellant improves asthma-related quality of life. American Journal of Respiratory and Critical Care Medicine 2002;165(Suppl 8):A107.
58. Pearlman D, Kerwin E, Kim K, Murray A, Fischer T, Wu W, et al.Fluticasone propionate HFA-134 A significantly improves asthma control in inhaled corticosteroid dependent asthmatics. American Journal of Respiratory and Critical Care Medicine 2002;165(Suppl 8):A770.
59. Meijer 1999 {published data only} * Meijer RJ, Kerstjens HA, Arends LR, Kauffman HF, Koeter GH, Postma DS. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax 1999;54(10):894-9.
60. Nathan 2000 {published data only} FLTA2016. http://ctr.gsk.co.uk 2005.
61. * Nathan RA, Li JTC, Finn A, Jones R, Payne E, Wolford JP, et al.A dose ranging study of fluticasone propionate administered once daily viamultidose powder inhaler to patients withmoderate asthma. Chest 2000;118(2):296-302.
62. Nelson 1999 {published data only} FLTA2002. http://ctr.gsk.co.uk 2005.
63. * Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ, Webb DR, Wolford JP, Mahajan PS, Hamedani AG, Shah T, Harding SM. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. Journal of Allergy & Clinical Immunology 1999;103(2 Pt 1):267-75.
64. Nimmagadda SR, Spahn JD, Nelson HS, Jenkins J, Szefler SJ, Leung DY. Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma. Annals of Allergy Asthma & Immunology 1998;81(1):35-40.
65. Nieto 2001 {published data only} Nieto ML, De Diego A, Perpina M, Compte L, Macian V. Are bronchial hyperresponsiveness and exhaled nitric oxide related in asthma? Effects of fluticasone. European Respiratory Journal 2001;18(Supp 33):335s.
66. Noonan 1995 {published data only} * Noonan M, Chervinsky P, Busse WW, Weisberg SC, Pinnas J, de Boisblanc BP, Boltansky H, Pearlman D, Repsher L, Kellerman D. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. American Journal of Respiratory & Critcal Care Medicine 1995;152(5 Pt 1):1467-73.
67. Okamoto LJ, Noonan M, DeBoisblanc BP, Kellerman DJ. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Annals of Allergy Asthma & Immunology 1996;76(5):455-61.
68. Noonan 1998 {published data only} Noonan MJ, Chervinsky P, Wolfe J, Liddle R, Kellerman DJ, Crescenzi KL. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. Journal of Asthma 1998;35(2):153-64.
69. O'Sullivan 2002 {published data only} O'Sullivan S, Cormican L, Murphy M, Poulter LW, Burke CM. Effects of Varying Doses of Fluticasone Propionate on the Physiology and Bronchial Wall Immunopathology in Mild-to-Moderate Asthma. Chest 2002;122(6):1966-72.
70. 2° for adenosine in asthma patients. American Journal of Respiratory and Critical Care Medicine 2002;165(Suppl 8):A768.
71. Pearlman 1997 {published data only} Mahajan P, Okamoto LJ, Schaberg A, Kellerman D, Schoenwetter WF. Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. Journal of Asthma 1997;34(3):227-34.
72. * Pearlman DS, Noonan MJ, Tashkin DP, Goldstein MF, Hamedani AG, Kellerman DJ, Schaberg A. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Annals of Allergy Asthma & Immunology 1997;78(4):356- 62.
73. Pearlman 1999 {published data only} FLTA3015. http://ctr.gsk.co.uk. 2005.
74. * Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, et al.Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Annals of Allergy, Asthma, & Immunology 1999;82(3):257-65.
75. Peden 1998 {published data only} FLTA2006. http://ctr.gsk.co.uk 2005.
76. Noonan M, Berger W, Thomas R, Pinnas A, Nayak A, Hendricks V, et al.Inhaled fluticasone propionate dry powder administered via Diskus or Diskhaler is safe and effective in pediatric patients with chronic asthma. European Respiratory Journal 1997;10(Suppl 25):221S.
77. * Peden DB, Berger WE, Noonan MJ, Thomas MR, Hendricks VL, Hamedani AG, et al.Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. Journal of Allergy & Clinical Immunology 1998;102(1):32-8.
78. Peden 1998a {published data only} FLTA2006. http://ctr.gsk.co.uk 2005.
79. Noonan M, Berger W, Thomas R, Pinnas A, Nayak A, Hendricks V, et al.Inhaled fluticasone propionate dry powder administered via Diskus or Diskhaler is safe and effective in pediatric patients with chronic asthma. European Respiratory Journal 1997;10(Suppl 25):221S.
80. * Peden DB, Berger WE, Noonan MJ, Thomas MR, Hendricks VL, Hamedani AG, et al.Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. Journal of Allergy & Clinical Immunology 1998;102(1):32-8.
81. Pinnas 2005 {published and unpublished data} FAP3008. A randomized, double-blind, parallel group, placebo-controlled 12-week trial of inhaled fluticasone propionate 88mcg BID, 220mcg BID, and 440mcg BID versus placebo in propellant GR106642X in adolescent and adult subjects with asthma who are maintained on bronchodilator therapy. www.clinicalstudyresults.org.
82. * Pinnas JL, Noonan MJ, Weinstein SF, Chervinsky P, Scott CA, Herje NE, et al.Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma. Journal of Asthma 2005;42(10):865-71.
83. Weinstein S, Korenblat P, Raphael G. Fluticasone propionate HFA 134-a significantly improves asthma control in inhaled corticosteroid naïve asthmatics. American Journal of Respiratory Critical Care Medicine 2002;165(8):A770.
84. Raphael 1999 {published data only} Raphael GD, Lanier RQ, Baker J, Edwards L, Rickard K, Lincourt WR. A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. Journal of Allergy & Clinical Immunology 1999;103(5 Pt 1):796-803.
85. SAM40012 {unpublished data only} * SAM40012. www.clinicalstudyresults.org 2001.
86. Sheffer 1996 {published data only} Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. Journal of Family Practice 1996;42(4):369-75.
87. Sorkness 1999 {published data only} Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clinical Therapeutics 1999;21(2):353-67.
88. Sorkness 1999a {published data only} Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisolone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clinical Therapeutics 1999;21(2):353-67.
89. Verona 2003 {published data only} FAS30006. http://ctr.gsk.co.uk 2005.
90. Verona E, Petrov D, Cserhati E, Hofman J, Geppe N, Davies P. A long term study to compare the safety and efficacy of Fluticasone Propionate (FP) 200mcg/day with 400mcg/day in asthmatic children aged 4-11 years. Journal of Allergy and Clinical Immunology 2001;107(2):s105.
91. Verona E, Petrov D, Cserhati E, Hofman J, Geppe N, Davies P. Fluticasone propionate in asthmatic children:a long term dose comparison of safety and efficacy. European Respiratory Journal 2001;18(Suppl 33):288s.
92. * Verona E, Petrov D, Cserhati E, Hofman J, Geppe N, Medley H, et al.Fluticasone propionate in asthma: a long term dose comparison study. Archives of Disease in Childhood 2003;88(6):503-9.
93. Wallin 2003 {published data only} * Wallin A, Sue-Chu M, Bjermer L, Ward J, Sandstrom T, Lindberg A, et al.Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. Journal of Allergy & Clinical Immunology 2003;112(1):72-8.
94. Wilson SJ, Ward JA, Djukanovic R, Wallin A, Sue-Chu M, Sandstrom T, et al.Effects of high and low dose inhaled fluticasone propionate (FP) compared to low dose FP combined with salmeterol (SAL) on airway inflammation in asthma. American Journal of Respiratory and Critical Care Medicine 2000;161(Suppl 3):A196.
95. Wasserman 1996 {published data only} Wasserman SI, Gross GN, Schoenwetter WF, Munk ZM, Kral KM, Schaberg A, Kellerman DJ. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. Journal of Asthma 1996;33(4):265-74.
96. Wolfe 1996 {published data only} * Wolfe JD, Selner JC, Mendelson LM, Hampel FJr, Schaberg A. Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clinical Therapeutics 1996;18(4):635-46.
97. Ayres 2000 {published data only} * Ayres JG, Millar AB, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. Respiratory Medicine. 2000;94(Suppl B):S42-50.
98. Bisgaard 1999 {published data only} Bisgaard H. Efficacy of inhaled fluticasone propionate in the treatment of young children with asthmatic symptoms: a dose comparison study. American Journal of Respiratory & Critical Care Medicine 1998;157(3):A711.
99. * Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. American Journal of Respiratory & Critical Care Medicine 1999;160(1):126-31.
100. Dorini 2001 {published data only} * Dorini S, Pelucchi A, Leone C, Mastropasqua B, Guarnieri R, Chetta A, et al.Eosinophil apoptosis in induced sputum (IS) from patients with mild symptomatic asthma during treatment with Fluticasone propionate (FP). European Respiratory Journal 2001;18(Suppl 33):337s.
101. FLTA2007 {unpublished data only} FLTA2007. http://ctr.gsk.co.uk.
102. Fowler 2002 {published data only} * Fowler SJ, Orr LC, Sims EJ, Wilson AM, Currie GP, McFarlane L, et al.Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest 2002;122(2):618-23.
103. Harrison 2001 {published data only} * Harrison TW, Wisnieswki A, Honour J, Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001;56:186-91.
104. Kelly 2001 {unpublished data only} Kelly MM, Leigh R, Parameswaran K, Jayaram L, Belda J, Goodwin S, et al.Establishing dose response and relative potencies of inhaled corticosteroids. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23. 2001.
105. Laforce 2000 {published data only} * Laforce CF, Pearlman DS, Ruff ME, Silvers WS, Weinstein SW, Clements DS, et al.Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Annals of Allergy, Asthma and Immunology 2000;85(5):407-15.
106. Lipworth 1997 {published data only} Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax 1997;52(8):686-9.
107. Lundback 1993 {published data only} Lundback B, Alexander M, Day J, Hebert J, Holzer R, Van Uffelen R, et al.Evaluation of fluticasone propionate (500micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler. Respiratory Medicine 1993;87:609-20.
108. Lundback 1994 {published data only} Lundback B, Dahl R, De Jonghe M, Hyldebrandt N, Valta R, Payne SL. A comparison of fluticasone propionate when delivered by either the metered-dose inhaler or the Diskhaler in the treatment of mild-to-moderate asthma. European Journal of Clinical Research 1994;5:11-19.
109. Medici 2000 {published data only} * Medici TC, Grebski E, Häcki M, Rüegsegger P, Maden C, Efthimiou J. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects. Thorax 2000;55:375-82.
110. Medici TG, Grebski E, Hacki M, Ruegsegger P, Maden C, Efthimiou J. One-year treatment with inhaled fluticasone propionate or beclomethasone dipropionate does not affect bone density and bone metabolism. A randomised, parallel group study in adult asthmatics. American Journal of Respiratory & Critical Care Medicine 1998;157:A407.
111. Murray 1998 {unpublished data only} * Murray JJ, Friedman B, Chervinsky P, Fogarty C, Baker JW, Rogenes PR, et al.Fluticasone propionate (FP) is more effective than higher doses of beclomethasone dipropionate (BDP) in patients with moderate asthma. American Journal of Respiratory and Critical Care Medicine 1998;157(Suppl 3):A407.
112. Pieters 1998 {published data only} Pieters WR, Stallaert RA, Prins J, Greefhorst AP, Bosman HG, van Uffelen R, et al.A study on the clinical equivalence and patient preference of fluticasone propionate 250 mcg twice daily via the Diskus/Accuhaler inhaler or the Diskhaler in adult asthmatic patients. Journal of Asthma 1998;35(4):337-45.
113. Visser 2001 {published and unpublished data} Visser MJ, Brand PLP, Kamps AWA, Duiverman EJ, Kauffman HF, Postma DS. One year treatment with different schedules of inhaled fluticasone propionate in childhood asthma: effects on lung function and immunological parameters. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23; www.abstracts2view.com 2001.
114. Visser MJ, Duiverman EJ, Postma DS, Arends LR, Brand PLP. High doses of inhaled fluticasone propionate dose-dependently suppress adrenal cortical function in asthmatic children. European Respiratory Journal 2001;18(Supp 33):290s.
115. * Visser MJ, Postma DS, Arends LR, De Vries TW, Duiverman EJ, Brand PL. One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. American Journal of Respiratory and Critical Care Medicine 2001;164:2073-7.
116. Visser MJ, Postma DS, Duiverman EJ, Arends LR, Kauffman HF, Brand PLP. Influence of fluticasone propionate on levels of exhaled nitric oxide in asthmatic children: a dose response study. European Respiratory Journal 2001;18(Supp 33):40s.
117. Wittmann 1999 {unpublished data only} Wittmann M, Thomas A, Petro W. Does doubling the inhaled steroid dosage at the beginning of an asthma therapy lead to a faster improvement of pathology or pulmonary function? [Führt die Verdopplung der inhalativen Steroiddosis zu Beginn einer Asthmatherapie zu enier schnelleren Verbesserung von Symptomatik oder Lungenfunktion?]. Pneumologie 1999;53(SH1).
118. Wolfe 2000 {published data only} Stanford R, Wightman D, Lincourt W, Edwards L, Crim C. Patient satisfaction with fluticasone propionate 250μg once daily. American Journal of Respiratory and Critical Care Medicine 2002;165(Suppl 8):A769.
119. * Wolfe J, Rooklin A, Grady J, Munk ZM, Stevens A, Prillaman B, et al.Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. Journal of Allergy and Clinical Immunology 2000;105(6 pt 1):1153-61.
120. ZuWallack 2000 {published data only} ZuWallack R, Adelglass J, Clifford DP, Duke SP, Wire PD, Faris M, Harding SM. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 2000;118(2):303- 12.
121. Bukovskis 2005 {published data only} Bukovskis M, Jurka N. Increase of neutrophil leukocyte count in induced sputum in patients on the treatment with high dose inhaled steroids [Abstract 303]. XIX World Allergy Organization Congress. 2005.
122. Osur 1998 {unpublished data only} * Osur S, Chervinsky P, Herie N, Harding S, Kellerman D. Long term effects of fluticasone propionate (FP) inhalation aerosol in subjects with asthma. American Journal of Respiratory and Critical Care Medicine 1998;157(Suppl 3):A405.
123. Adams 2008 Adams NP, Bestall JC, Lasserson TJ, Jones PW. Inhaled fluticasone propionate versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4.
124. Ayres 2000 Ayres JG, Millar AB, Sykes AP. [Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group]. Respiratory Medicine 2000;94(Suppl B):S42-50.
125. BTS 1997 British Thoracic Society. The British guidelines on asthma management 1995 review and position statement. Thorax 1997;52(Suppl 1):S1-20.
126. BTS 2003 The British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax 2003;58(Suppl 1).
127. Cates 2008 Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2]
128. Egger 2001 Egger M, Davey Smith G, Altman DG. Systematic Reviews in Healthcare: Meta-analysis in Context. BMJ Books, 2001.
129. GINA 1995 National Asthma Education and Prevention Program. Global initiative for asthma management and prevention NHBLI/WHO workshop report. National Institute of Health, Bethseda, MD 1995, issue NIH Publication No. 95-3659.
130. Gross 1999 Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. [Hydrofluoroalkane-134a beclomethasone dipropionate, 400 mug, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 mug, for the treatment of moderate asthma]. Chest 1999;115(2):343-51.
131. NHLBI 1997 National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Managment of Asthma, Expert Panel Report No. 2. Bethesda MD: NIH/National Heart, Lung and Blood Institute 1997, issue NIH Publication No. 97-4051.
132. Tattersfield 2004 Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proceedings of the American Thoracic Society 2004;1:171-5.